It is now about 20 years since the first case of a gain-of-function mutation involving the as-yet-
unknown actor in cholesterol homeostasis, proprotein convertase subtilisin/kexin type 9 …

Atherosclerotic cardiovascular disease (ASCVD) remains a leading cause of morbidity and
mortality despite excellent pharmacological and revascularization approaches. Low-density …

Importance The 2018 American Heart Association/American College of Cardiology
Multisociety Guideline on the Management of Blood Cholesterol identified patients with …

The significant reduction in 'ischemic time'through capillary diffusion of primary
percutaneous intervention (pPCI) has rendered myocardial-ischemia reperfusion injury …

Cardiovascular diseases (CVD) cause about 1/3 of global deaths. Therefore, new strategies
for the prevention and treatment of cardiovascular events are highly sought-after. Vitamin E …

Acute Coronary Syndrome (ACS) remains one of the most frequent causes of morbidity and
mortality in the world. Although the age-and gender-adjusted incidence of ACS is …

Purpose To evaluate the potential association between the lowering of low-density
lipoprotein cholesterol (LDL-C) with contemporary lipid-lowering medicines and cognitive …

Statins are a class of cholesterol‐lowering drugs which act inhibiting the enzyme 3‐hydroxy‐
3‐methyl‐glutaryl‐coenzyme A reductase and are commonly used for preventing or treating …

Dyslipidemia is a major risk factor for cardiovascular (CV) disease, which is the leading
cause of death globally. Acute coronary syndrome (ACS) is a common cause of death …

PCSK9i represent a potent class of lipid-lowering therapies that are well tolerated and
effective in a wide group of patients with high-risk atherosclerotic cardiovascular disease …